- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02367053
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator
The trial is a randomized, double-blind First in Human trial to evaluate the safety and tolerability of ZP4207 in healthy volunteers (HV) and in insulin-induced hypoglycemic T1D (type 1 diabetes) subjects as compared to native glucagon. The trial includes two parts.
Part 1 includes dose escalation of ZP4207 in cohorts of 8 subjects. In each cohort, subjects will be randomized 3:1 to receive either a single ascending dose of ZP4207 (6 subjects) or a single fixed dose (SD) of native glucagon (2 subjects). The doses will be administered s.c. in 4-5 cohorts and i.m. in 3 cohorts.
Part 2 includes two sequence groups of 10 hypoglycemic T1D subjects. The subjects will be treated with fixed single doses of ZP4207 and native glucagon s.c. in a sequential cross-over design in a randomized treatment order.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Neuss, Alemania, 41460
- Profil GmbH
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
- Male subjects which are healthy for part 1; for part 2 male subjects with T1D
- Age between 18 and 50 years, both inclusive.
- Body weight between 70 and 90 kg, both inclusive.
- Subjects must be in good health according to age (medical history, physical examination, vital signs, ECG, lab assessments), as judged by the investigator
A subject who is surgically sterilized or must be willing to refrain from sexual intercourse during the trial and until one month after completion of the trial or if sexually active, using condom and partner practices contraception during the trial and until one month after completion of the trial.
For part 2, in addition:
- Male subjects with T1D for at least one year, as defined by the American Diabetes Association.
- Having been treated with insulin for T1D for at least 1 year.
- Stable disease with HbA1c < 8.5 %.
- Stable insulin treatment during participation in trial and 3 month prior to the screening visit.
Exclusion Criteria:
- Known or suspected allergy to trial product(s) or related products.
- Previous participation (randomization) in this trial.
- Receipt of any investigational drug within 3 months prior to screening.
- A history or presence of cancer, diabetes (part 1 only), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, hematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases.
- Clinically significant illness within 4 weeks before screening, as judged by the investigator
- Carrier of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies.
- Positive result of test for HIV antibodies.
- Any clinically significant abnormal hematology,biochemistry or urinalysis screening tests, as judged by the Investigator.
- Clinically significant abnormal ECG at screening as evaluated by Investigator.
- Donation of blood or plasma in the past month, or in excess of 500 ml within 12 weeks prior to screening.
- A significant history of alcoholism or drug/chemical abuse, or who has a positive result in the urine drug screen, or who consumes more than 28 units of alcohol per week (one unit of alcohol equals about 250 ml of beer, 1 glass of wine, or 20 ml of spirits).
- Habitual smoking, i.e., daily smoking or more than 7 cigarettes/week within the last 3 months prior to screening. Subjects have to accept refraining from smoking while at the clinical site.
- Subjects with mental incapacity or language barriers which preclude adequate understanding or cooperation, who are unwilling to participate in the trial, or who in the opinion of the Investigator should not participate in the trial.
- Surgery or trauma with significant blood loss within the last 2 months prior to screening.
Any condition interfering with trial participation or evaluation or that may be hazardous to the subject.
For part 2, in addition
- Severe hypoglycemic events within one year prior to screening, as judged by the investigator.
- Significant changes in basal insulin within 3 weeks before screening, as judged by the investigator.
- Clinically relevant diabetic complications (macrovascular disease with symptoms of coronary artery disease or peripheral vascular disease, microvascular disease with symptoms of neuropathy, gastroparesis, retinopathy, nephropathy, or poor blood glucose control with polyuria, polydipsia, or weight loss), as judged by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: ZP4207
single dose of ZP4207 in ascending doses (s.c. and i.m.)
|
|
Comparador activo: native glucagon
single fixed dose of glucagon
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Safety and Tolerability: Number of participants with adverse events
Periodo de tiempo: 28 days
|
28 days
|
Safety and Tolerability: Changes or findings from baseline in clinical safety laboratory assessments
Periodo de tiempo: 28 days
|
28 days
|
Safety and Tolerability: Changes or findings from baseline in physical examination
Periodo de tiempo: 28 days
|
28 days
|
Safety and Tolerability: Changes or findings from baseline in vital signs
Periodo de tiempo: 28 days
|
28 days
|
Safety and Tolerability: Changes or findings from baseline in ECG
Periodo de tiempo: 28 days
|
28 days
|
Safety and Tolerability: Findings in local tolerability
Periodo de tiempo: 28 days
|
28 days
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Pharmacokinetics (PK): Area under the curve (AUC) from time-point 0 until 300min
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: maximum observed concentration of ZP4207 (Cmax)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: time to maximum observed concentration of ZP4207 (tmax)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: terminal elimination rate constant estimated during the terminal phase of ZP4207 (λz)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: the terminal plasma elimination half-life of ZP4207 (t½),
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: apparent volume of distribution of ZP4207 based on plasma concentration values (Vz), estimated during the terminal Phase (f): (Vz/f)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: apparent plasma clearance rate of ZP4207(CL) estimated during the terminal Phase (f)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacokinetics: mean residence time for plasma ZP4207 (MRT)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacodynamics (PD): Area under the Plasma glucose curve from time-point 0 until 300 min (AUCgluc 0-300)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacodynamics: maximum observed concentration (Cmax)
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacodynamics: time to maximum observed concentration (tmax)TPG≥70mg/dL
Periodo de tiempo: 5 hours
|
5 hours
|
Pharmacodynamics: Time to plasma glucose equal or above (70 mg/dL)
Periodo de tiempo: 5 hours
|
5 hours
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thomas Jax, MD/PhD, Profil GmbH
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ZP4207-14013
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Glucagón
-
Xeris PharmaceuticalsTerminadoHipoglucemia | Diabetes Mellitus, Tipo 1Estados Unidos, Canadá